February 15, 2006 (Vol. 26, No. 4) Visualizing the Interactions Between a Potential Drug and Its Proposed Target LigandScout, released this month by Inte:Ligand (www.inteligand. com), features a 3 ...

The in silico trial market is evaluated to grow to $2,88 billion in annual revenue by 2022, when it will still represent only a small fraction of $165 billion annual drug R&D spent [1].

Veritas In Silico Inc. has partnered with Liverpool ChiroChem to develop mRNA-targeted small molecule drugs, aiming to create innovative therapeutics for various diseases.

There is increasing focus on the development of new cell and gene therapies (CGT) in rare disease. The majority of CGT approvals have been based on small, open-label, non-randomized, single-arm ...

A British ‘tech bio’ start-up, Basecamp Research, says the combination of machine learning, public datasets, and a graph-based Knowledge Graph from Neo4j is proving critical to its mission of helping ...